Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients

NCT04468646 is registered in ClinicalTrials.gov with Prof. Dr. Fridoon Jawad Ahmad as lead sponsor.

NCT NCT04468646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04468646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients
Lead sponsor
Prof. Dr. Fridoon Jawad Ahmad
Phase
Phase 3
Overall status
Unknown status
Start date
June 15, 2020
Completion date
August 30, 2020
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neurokinin 1 receptor, substance p, respiratory illness, inflammation, covid-19, coronavirus